Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business. Fredun expects blended revenue growth of around 30% to 35% year-on-year over the next 3 years, driven by both new age brands (35%-45% growth) and vintage business (15%-20% growth).
From Fredun Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business.
- The pet care segment (~INR40-45 crore currently) aims for 40%-50% year-on-year growth for the next 3-4 years, with further acceleration expected once cat food and diagnostics revenues start contributing.
- Functional foods sales are expected to grow rapidly, with INR18-24 crore targeted this year alone and cat food launch planned by Q3/Q4 FY27.
- GX (generic pharmaceuticals) division projects 25%-35% growth annually over the next 5 years, expanding presence from 19 states with a currently small base (~INR100-110 crore).
- Overall, revenue guidance for FY27 is conservatively set around INR800 crores, with potential to exceed but no committed target for INR1,000 crores.
- Long-term growth also supported by capacity expansion (INR30-40 crore CapEx per year) and planned acquisitions.
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals plans significant capital expenditure (CapEx) to expand manufacturing capacity.
- Target is to have one of the largest manufacturing units at a single location in the country by end of December 2028/early 2029.
- CapEx planned for FY27 is around INR 30 to 40 crores.
- Similar CapEx budget of INR 30 to 40 crores is expected for the following year as well.
- Maintenance CapEx is estimated at around 2% of revenue (~INR 20 crores at INR 1000 crore revenue) to upgrade facilities and comply with cGMP regulations.
- Strategic acquisitions are also planned in the pet care segment, with some being small and some big, all fundamental to the long-term growth story. Updates will be provided to investors as these acquisitions occur.
- Investment in the pet care ecosystem including launching new plants for functional foods and diagnostics centers is ongoing.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals mentioned a boost in Q1 FY27 sales partly due to booking additional orders in the last quarter of the previous year.
- They offered customers better pricing, encouraging them to book further orders, which contributed to a higher order book.
- No specific numerical value of the current order book or pending orders was disclosed.
- The management expects growth to continue at similar levels in coming quarters, indicating a healthy and active order pipeline.
- The company focuses on consistency in product availability and new product introductions to maintain order momentum.
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q1 FY27 results?
Fredun Pharmaceuticals targets a blended growth rate of approximately 30%-35% year-on-year over the next 3 years, combining growth from new age brands and vintage business. Fredun expects blended revenue growth of around 30% to 35% year-on-year over the next 3 years, driven by both new age brands (35%-45% growth) and vintage business (15%-20% growth).
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.4 with a market cap of ₹2,373 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals plans significant capital expenditure (CapEx) to expand manufacturing capacity. - Target is to have one of the largest manufacturing units at a single location in the country by end of December 2028/early 2029. - CapEx planned for FY27 is around INR 30 to 40 crores. - Similar CapEx budget of INR 30 to 40 crores is expected for the following year as well. - Maintenance CapEx is estimated at around 2% of revenue (~INR 20 crores at INR 1000 crore revenue) to upgrade facilities and comply with cGMP regulations. - Strategic acquisitions are also planned in the pet care segment, with some being small and some big, all fundamental to the long-term growth story.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.